<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629849</url>
  </required_header>
  <id_info>
    <org_study_id>1310.2</org_study_id>
    <secondary_id>2012-000926-23</secondary_id>
    <nct_id>NCT01629849</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 Tablets in Otherwise Healthy Controlled Asthmatic Subjects (Phase I, Randomised, Placebo-controlled, Double-blind Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, pharmacokinetics including posology, and
      pharmacodynamics of multiple rising doses of BI 1021958 in otherwise healthy mild asthmatic
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with drug-related adverse events</measure>
    <time_frame>up to day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t after administration of the first dose)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point within the first dosing interval)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre,N (predose concentration of the analyte in plasma immediately before administration of the Nth dose after N-1 doses were administered</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal rate constant in plasma</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after oral administration)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal rate constant in plasma at steady state</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life of the analyte in plasma at steady state)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyte in the plasma at steady state following extravascular multiple dose administration)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase at steady state following extravascular administration)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg (average concentration)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF (peak trough fluctuation)</measure>
    <time_frame>up to 481:30 h</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>BI 1021958 qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple rising dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 1021958 qd</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo as tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1021958 bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple rising dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 1021958 bid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching palcebo as tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1021958 qd</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo to BI 1021958 qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1021958 bid</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1021958 bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1021958 bid</intervention_name>
    <description>tablets</description>
    <arm_group_label>Placebo to BI 1021958 bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1021958 qd</intervention_name>
    <description>tablet</description>
    <arm_group_label>BI 1021958 qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male and female subjects ofn non child-bearing potential

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions except mild controlled asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1310.2.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

